Funding
Funding not disclosed
Founders
Product
Problem
Hospitalized patients often face serious infections that are increasingly difficult to treat due to rising antibiotic resistance. Current treatment options may be limited, leading to complications and prolonged hospital stays.
Solution
Nabriva Therapeutics is a biopharmaceutical company focused on developing and commercializing novel anti-infective agents to combat serious infections. The company's pipeline includes innovative antibiotics designed to address the unmet needs of patients with life-threatening infections, such as community-acquired bacterial pneumonia (CABP) and complicated urinary tract infections (cUTI). Nabriva's approach involves identifying and developing therapies that can overcome existing resistance mechanisms and improve treatment outcomes for hospitalized patients. By focusing on novel mechanisms of action and targeted delivery, Nabriva aims to provide clinicians with effective tools to combat the growing threat of antibiotic-resistant bacteria.
Target Audience
The primary target audience includes hospitals, physicians, and other healthcare providers who treat patients with serious bacterial infections, as well as patients who are at risk of or are currently suffering from such infections.
Features
- Development of pleuromutilins, a novel class of antibiotics with a unique mechanism of action
- Focus on both intravenous and oral formulations for flexible administration
- Pipeline targeting multi-drug resistant (MDR) pathogens
- Programs designed to address infections in both hospital and community settings